Prognostic implication of histological oligodendroglial tumor component: Clinicopathological analysis of 111 cases of malignant gliomas

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Kanno, Hiromi ^a   Nishihara, Hiroshi ^a   Narita, Takuhito ^a   Yamaguchi, Shigeru ^a   Kobayashi, Hiroyuki ^a   Tanino, Mishie ^a   Kimura, Taichi ^a   Terasaka, Shunsuke ^a   Tanaka, Shinya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; NIMUSTINE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; SCHOOL CHILD; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; YOUNG ADULT;

EID: 84864251241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041669     Document Type: Article

References (20)

1. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, et al. (1997) Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 38: 911-914.
2. Shaw EG, Scheithauer BW, O'Fallon JR, (1997) Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 31: 273-278.
3. Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, et al. (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97: 1063-1071.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors (2007) WHO Classification of Tumours of the Central Nervous System, 4th Edition: IARC Press, Lyons. 164-172 p.
5. Pinto LW, Araujo MB, Vettore AL, Wernersbach L, Leite AC, et al. (2008) Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch 452: 481-490.
6. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, et al. (2006) Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65: 846-854.
7. Hilton DA, Penney M, Pobereskin L, Sanders H, Love S, (2004) Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology 44: 555-560.
8. Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, et al. (2001) Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 101: 311-320.
9. Salvati M, Formichella AI, D'Elia A, Brogna C, Frati A, et al. (2009) Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neurooncol 94: 129-134.
10. Miller CR, Dunham CP, Scheithauer BW, Perry A, (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24: 5419-5426.
11. Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, et al. (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14: 842-853.
12. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, et al. (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99: 467-473.
13. Salminen E, Nuutinen JM, Huhtala S, (1996) Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 32A: 1918-1923.
14. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, et al. (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880.
15. Aldape K, Burger PC, Perry A, (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131: 242-251.
16. Hartmann C, Mueller W, von Deimling A, (2004) Pathology and molecular genetics of oligodendroglial tumors. J Mol Med 82: 638-655.
17. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, et al. (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24: 2715-2722.
18. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, et al. (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18: 636-645.
19. Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, et al. (2003) Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 62: 1118-1128.
20. McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, et al. (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104: 1468-1477.